CRISPR Therapeutics Announces Third Quarter 2017 Financial Results and Provides Business Update – Markets Insider
|
CRISPR Therapeutics Announces Third Quarter 2017 Financial Results and Provides Business Update
Markets Insider “CRISPR Therapeutics substantially completed the preclinical activities in the third quarter for CTX001, our lead program targeting two hemoglobinopathies, Sickle Cell Disease and β-Thalassemia. Based on these accomplishments, we are on track to file a … |
